Concluding Remarks The indiscriminate use of antifungal drugs for prophylactic and empirical treatment of suspected invasive fungal diseases in high-risk individuals such as patients with cystic fibrosis, critically ill, or haemato–oncology patients is a worrying trend.
1
—
—